Future research should focus on developing small-molecule agents or biologics that specifically modulate APT1 activity and expression, potentially synergizing with existing therapeutic approaches to further enhance treatment efficacy in diabetic kidney disease. The gene discussed is LYPLA1; the disease is diabetic kidney disease.